Immunic

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Our mission is to develop novel and differentiated therapies for those suffering from chronic inflammatory and autoimmune diseases, and provide them with the highest quality of care.

Our vision is to become a leader in the discovery and development of innovative therapies for the treatment of chronic inflammatory and autoimmune diseases, with a commitment to patient-focused care.

Immunic, Inc. has been recognized multiple times by industry experts, including the 2017 Fierce Biotech Breakthrough Award and the 2018 Innovation in Treating Inflammatory Disease Award.